

Supplementary File

Antimicrobial resistance profiling and phylogenetic analysis of *Neisseria gonorrhoeae* clinical isolates from Kenya in a resource-limited setting

Meshack Juma¹⁺, Arun Sankaradoss²⁺, Redcliff Ndombi¹, Patrick Mwaura¹, Tina Damodar², Junaid Nazir², Awadhesh Pandit², Rupsy Khurana², Moses Masika¹, Ruth Chirchir¹, John Gachie¹, Sudhir Krishna², Ramanathan Sowdhamini², Omu Anzala^{1,*}, Iyer Meenakshi S^{2,*}

⁺ Equal contribution first authors

^{*}Corresponding authors (Iyer Meenakshi S: meenakshis@ncbs.res.in, Omu Anzala: oanzala@kaviuon.org)

1 KAVI Institute of Clinical Research, University of Nairobi, Nairobi, Kenya

2 National Centre for Biological Sciences, TIFR, Bangalore, Karnataka, India

1. Sample details

Supplementary Table 1: Demographic information of patients. Samples were taken with consent from >18 years old patients visiting STI clinics with genital discharge or fluid (watery, pus). CSW- commercial sex work, NG- *N. gonorrhoeae*, NM- *N. meningitidis*, MO- *Moraxella osloensis*, HIV- Human immunodeficiency virus. Only NG genomes were analysed further, genomes marked with * were found to have a lot of gaps and were not considered. R – Radio, B- Barazas, T- Television, F – Friends, N- Newspaper, O- Other sources.

ID	Enrol_No	District	CSW Duration Years	Clients Past Week	HIV Info Source	Education level	Services expected	Reads from organism
3	SW0002	Murang'a	1	0	R, B	2	Treatment and doctor examination	NG
4	SW0004	Kiambu	11	0	R	2	Doctor examination, HIV testing and treatment	NM
11	SW0280	Nyandarua	4	1	N,R,T,F	1	HIV test and STI screening	NM
12	SW0005	Murang'a	2	0	R	2	HIV test	NG
18	SW0018	Machakos	20	1	B	1	Doctor examination	NG
57	SW0011	Murang'a	5	0	T, F	0	HIV testing	NG
61	SW0032	Nairobi	4	2	O	2	Doctor examination	NG

81	SW0053	Murang'a	4	1	R	1	Doctor examination	NG* + MO
100A	SW0015	Kiambu	1	0	F	2	HIV test and STI screening	NG
196	SW0102	Kiambu	6	1	F	1	Doctor examination	NG* + MO
240	SW0223	Thika	6	1	F	1	Doctor examination	NG + MO
274	SW0236	Gem	1	1	R	1	Doctor examination	NG
285	SW0259	Murang'a	5	2	R	1	Doctor examination	NG
298	SW0274	Murang'a	10	1	F	1	Doctor examination	NG

2. Determining antibiotic susceptibility

1. E-test strips were allowed to come to room temperature before opening the container.
2. Using the Vitek colourimeter or standard turbidity tube, we prepared a suspension of the test organism in sterile Muller Hinton broth, the organism was inoculated until it reached sufficient turbidity equivalent to 0.5 McFarland standards.
3. Dacron swab was used to inoculate from the pure culture onto an agar plate, streaking in 3 directions i.e. over the entire agar surface.
4. Incubation was carried out at 37°C and CO₂ concentration (5%) and interpreted as per the instruction on the insert.


MIC's above a documented specific level for each antibiotic as per the CLSI guidelines constitute "resistance" of a strain to that antibiotic while MIC's above the normal MIC level but below the critical level for the definition of resistance constitute strains with decreased susceptibility to a given antibiotic.

Supplementary Table 2: MIC reference used in the study. MICs (µg/ml) for the interpretation of susceptibility of strains of *N. gonorrhoeae* to selected antimicrobial agents, as recommended by CLSI for interpretation of resistance.


Antimicrobial agents	Susceptible (S)	Intermediate (I)	Resistant (R)
Ceftriaxone	≤0.25 µg/ml	.	>0.25 µg/ml

Cefixime	$\leq 0.25 \mu\text{g/ml}$.	$> 0.25 \mu\text{g/ml}$
Ciprofloxacin	$\leq 0.06 \mu\text{g/ml}$	$0.12 - 0.5 \mu\text{g/ml}$	$> 1 \mu\text{g/ml}$
Spectinomycin	$\leq 32 \mu\text{g/ml}$	$64 \mu\text{g/ml}$	$> 128 \mu\text{g/ml}$
Erythromycin	$\leq 0.25 \mu\text{g/ml}$	$0.38 - 1.0 \mu\text{g/ml}$	$1.5 - 4.0 \mu\text{g/ml}$
Azithromycin	$\leq 0.25 \mu\text{g/ml}$	$0.5 \mu\text{g/ml}$	$> 1.0 \mu\text{g/ml}$
Tetracycline	$\leq 0.25 \mu\text{g/ml}$	$0.5 - 1.0 \mu\text{g/ml}$	$> 2 \mu\text{g/ml}$
Penicillin	$\leq 0.06 \mu\text{g/ml}$	$0.12 - 1.0 \mu\text{g/ml}$	$> 2 \mu\text{g/ml}$
Gentamycin	$\leq 4 \mu\text{g/ml}$	$8 - 16 \mu\text{g/ml}$	$> 32 \mu\text{g/ml}$

3. Genome assembly and read statistics



Supplementary Figure 1: Pipeline for *de novo* assembly. The workflow followed for *de novo* genome assembly, error correction and genome polishing using Canu and Minimap-Miniasm, has been depicted in the figure.



Supplementary Figure 2: Mappability of the reads to the reference genome. The number of reads vs depth and genome coverage for the nine strains has been plotted. We observe that the increase in reads/coverage does not necessarily indicate an increase in genome coverage.

4. Comparison of assembly statistics for assemblies obtained using different methods

Supplementary Table 3a: Assembly statistics for the reference-based assembly. Bwa-mem was used for the assembly followed by samtools and bcftools for deriving the consensus from the assembly.

Strain ids.	3	12	18	57	61	100A	200	274	285	298
Genome fraction (%)	99.677	99.772	99.654	99.87	99.867	99.793	97.83	99.386	99.839	99.675
Duplication ratio	1	1	0.998	1	0.999	1	1	0.999	0.999	0.998
# genomic features	1944 + 5 part	1950 + 4 part	1927 + 27 part	1949 + 5 part	1944 + 10 part	1950 + 4 part	1946 + 8 part	1921 + 33 part	1942 + 12 part	1936 + 18 part

Largest alignment	21468 53	21480 40	21425 64	21506 46	2149468	21490 55	21507 31	21360 56	21482 48	21429 53
Total aligned length	21468 53	21480 40	21425 64	21506 46	2149468	21490 55	21507 31	21360 56	21482 48	21429 53
NGA50	21468 53	21480 40	21425 64	21506 46	2149468	21490 55	21507 31	21360 56	21482 48	21429 53
LGA50	1	1	1	1	1	1	1	1	1	1
# misassemblies	0	0	0	0	0	0	0	0	0	0
Misassembled contigs length	0	0	0	0	0	0	0	0	0	0
# mismatches per 100 kbp	594.93	579.1	659.97	628.56	583.71	616.15	654.45	602.37	556.95	616.04
# indels per 100 kbp	2.38	3.4	5.12	3.16	3.44	3.16	5.53	9.48	6.05	10.29

Supplementary Table 3b: Assembly statistics for the *de novo* assembly derived from Minimap and Miniasm. Error correction was done for two rounds with Racon, followed by polishing with Nanopolish to get the final assembly.

Strain ids	3	12	18	57	61	100A	240	298	285	274
Genome fraction (%)	97.58	97.662	97.422	97.236	97.499	97.21	96.207	96.965	96.441	51.891
Duplication ratio	1.166	1.008	1.009	1.009	1.005	1.053	1.02	1.011	1.019	1.015
# genomic features	1886 + 36 part	1878 + 48 part	1869 + 56 part	1871 + 48 part	1881 + 41 part	1883 + 35 part	1855 + 37 part	1877 + 37 part	1872 + 36 part	438 + 894 part
Largest alignment	287696	34222 6	34371 1	32827 6	24988 0	33943 3	269000	36024 6	34012 3	41545

Total aligned length	2437622	21045 85	21115 49	20988 35	21104 45	21876 40	2095088	20978 42	21124 54	1134422
NGA50	153182	23993 4	17431 6	19998 0	23238 3	19788 3	189013	19490 4	19527 6	1988
LGA50	5	4	5	5	5	5	5	5	5	94
# misassemblies	33	21	31	28	22	34	36	33	30	150
Misassembled contigs length	2177529	21711 90	21640 91	21638 70	21599 24	22640 29	2223993	22187 92	22503 96	2175989
# mismatches per 100 kbp	1038.49	830.83	898.02	842.11	852.36	886.75	917.56	874.14	859.3	4569.89
# indels per 100 kbp	563.37	453.76	331.82	485.44	380.52	509.16	447.87	397.79	376.99	306.62

Supplementary Table 3c: Assembly statistics for the *de novo* assembly derived from Canu. Error-correction and trimming were done using Canu followed by genome polishing with Nanopolish.

Strain ids.	3	12	18	57	61	100A	240	298	285	274
Genome fraction (%)	97.58	97.662	97.422	97.236	97.499	97.21	96.207	96.965	96.441	51.891
Duplication ratio	1.166	1.008	1.009	1.009	1.005	1.053	1.014	1.011	1.019	1.015
# genomic features	1886 + 36 part	1878 + 48 part	1869 + 56 part	1871 + 48 part	1881 + 41 part	1883 + 35 part	1873 + 40 part	1877 + 37 part	1872 + 36 part	438 + 894 part
Largest alignment	28769 6	34222 6	34371 1	32827 6	24988 0	33943 3	334358	36024 6	34012 3	41545
Total aligned length	24376 22	21045 85	21115 49	20988 35	21104 45	21876 40	2113499	20978 42	21124 54	11344 22

NGA50	15318 2	23993 4	17431 6	19998 0	23238 3	19788 3	195256	19490 4	19527 6	1988
LGA50	5	4	5	5	5	5	5	5	5	94
# misassemblies	33	21	31	28	22	34	35	33	30	150
Misassembled contigs length	21775 29	21711 90	21640 91	21638 70	21599 24	22640 29	2238288	22187 92	22503 96	21759 89
# mismatches per 100 kbp	1038.4 9	830.83	898.02	842.11	852.36	886.75	891.39	874.14	859.3	4569.8 9
# indels per 100 kbp	563.37	453.76	331.82	485.44	380.52	509.16	407.19	397.79	376.99	306.62

5. Sequence-typing analysis for the strains

Supplementary Table 4a: Sequence-typing results of the nine strains using the PubMLST scheme. We observed novel alleles for the gene *pgm* in all the strains, *pdhC* in six strains, *adk* in four strains and *aroE* in two strains.

Strain ids	<i>abcZ</i>	<i>Adk</i>	<i>aroE</i>	<i>fumC</i>	<i>Gdh</i>	<i>pdhC</i>	<i>pgm</i>
3	59	67	67	111	148	N	N
12	59	N	N	158	148	N	N
18	59	39	N	158	148	N	N
57	59	112	67	158	148	71	N
61	59	39	170	158	148	N	N
100A	59	N	67	158	148	71	N
240	126	N	67	157	148	N	N
274	59	39	170	237	148	N	N
285	126	N	806	158	148	783	N
298	59	N	806	157	150	N	N

Supplementary Table 4b: Sequence-typing results of the nine strains using NGMAST scheme. Novel *por* and *tbpB* alleles were observed in strains except for strain 3 where the porin allele matched POR139 and strain 285 where *tbpB* allele matched TBPB219/TBPB198.

Strain ids.	<i>por</i>	<i>tbpB</i>
3	POR139	N
12	N	N
18	N	N
57	N	N
61	N	N
100A	N	N
240	N	N
274	N	N
285	N	TBPB219/TBPB198
298	N	N

Supplementary table 4c: Sequence-typing results of the nine strains using NGSTAR scheme. New alleles for *penA* were observed in all the strains, new *mtrR* alleles were observed in seven strains and new *parC* alleles were observed in two strains. N: Novel allele.

Strain ids.	23S1 rDNA	<i>gyrA</i>	<i>mtrR</i>	<i>parC</i>	<i>penA</i>	<i>ponA</i>	<i>porB</i>
3	23S_100.0	gyrA_100.0	mtrR_10.0	parC_2.0	N	ponA_1.0	porB_100.0
12	23S_100.0	gyrA_7.0	N	parC_49.0	N	ponA_100.0	porB_100.0
18	23S_100.0	gyrA_7.0	N	N	N	ponA_1.0	
57	23S_100.0	gyrA_7.0	N	parC_7.0	N	ponA_1.0	
61	23S_100.0	gyrA_100.0	mtrR_54.0	parC_1.0	N	ponA_100.0	porB_100.0
100A	23S_100.0	gyrA_7.0	N	parC_7.0	N	ponA_1.0	
240	23S_100	gyrA_5.0	mtrR_69.0	N	N	ponA_100.0	
274	23S_100.0	gyrA_100.0	N	parC_2.0	N	ponA_100.0	
285	23S_100.0	gyrA_5.0	N	N	N	ponA_1.0	porB_3.0
298	23S_100.0	gyrA_100.0	N	parC_49.0	N	ponA_100.0	porB_3.0

Supplementary Table 4d: Sequencing depth for the gene loci in PubMLST, NGMAST and NGSTAR scheme. The sequencing depth for the genic loci listed in (a)-(c) has been provided.

Strain id		3	12	18	57	61	100	24	274	285	298
	gene						A	0			
MLST	<i>abcZ</i>	182	340	189	310	40	768	53	193	84	168
	<i>adk</i>	541	352	211	362	52	827	48	209	70	205
	<i>aroE</i>	606	367	222	404	56	915	47	186	84	178
	<i>fumC</i>	525	333	193	368	38	877	43	193	79	191
	<i>gdh</i>	454	363	201	367	46	819	44	210	70	196
	<i>pdhC</i>	459	340	199	342	43	818	52	215	81	183
	<i>pgm</i>	494	347	226	362	54	809	54	212	67	179
NGMAS T	<i>por</i>	509	344	268	389	52	843	55	242	94	221
	<i>tbpB</i>	521	363	157	385	65	801	50	203	69	160
NGSTA R	23S rRNA1	551	388	244	346	66	1138	52	242	90	245
	23S rRNA2	601	366	253	347	60	1012	46	177	74	182
	23S rRNA3	475	300	181	361	58	885	70	217	86	191
	23S rRNA4	423	287	227	350	33	423	47	204	75	189
	<i>gyrA</i>	473	303	209	360	42	838	45	184	82	226
	<i>mtrR</i>	494	338	229	364	44	790	38	229	111	218
	<i>parC</i>	476	326	247	308	44	777	53	187	73	203
	<i>penA</i>	582	384	209	273	56	867	42	217	92	125
	<i>ponA</i>	536	337	225	373	47	829	56	209	98	208
	<i>porB</i> (full_gene)	509	345	262	360	50	904	55	241	96	226

6. Antibiotic MICs

Supplementary Table 5: MIC values for different antibiotics

The MIC values ($\mu\text{g/ml}$) and the interpretations for different antibiotics for the nine strains. S- Susceptible, R – Resistant, I – Intermediate

Strain id.	Ceftriaxone ($\mu\text{g/ml}$)	Ciprofloxacin ($\mu\text{g/ml}$)	Spectinomycin ($\mu\text{g/ml}$)	Cefixime ($\mu\text{g/ml}$)	Gentamicin ($\mu\text{g/ml}$)	Cefoxitin ($\mu\text{g/ml}$)
3	0.016 (S)	0.032 (S)	0.75 (S)	0.016 (S)	0.064 (S)	0.016 (S)
12	0.016 (S)	3 (R)	8 (S)	<0.016 (S)	8 (I)	0.016 (S)
18	< 0.016 (S)	0.032 (S)	0.75 (S)	0.016 (S)	0.064 (S)	0.016 (S)
57	< 0.032 (S)	3 (R)	4 (S)	0.016 (S)	4 (S)	0.016 (S)
61	0.016 (S)	3 (R)	8 (S)	<0.016 (S)	3 (S)	0.016 (S)
100A	< 0.016 (S)	<0.016 (S)	8 (S)	<0.016 (S)	4 (S)	<0.016 (S)
240	<0.016 (S)	0.75 (I)	2 (S)	<0.016 (S)	1 (S)	0.016 (S)
274	< 0.016 (S)	< 0.016 (S)	4 (S)	<0.016 (S)	3 (S)	0.016 (S)
285	0.047 (S)	1 (I)	4 (S)	<0.016 (S)	1.5 (S)	0.125 (S)
298	0.016 (S)	0.75 (I)	4 (S)	<0.016 (S)	3 (S)	0.016 (S)

7. Mutations resulting in AMR

Multiple mutations have been reported in many genes conferring resistance to different classes of antibiotics in *N. gonorrhoeae*. A brief overview of the mutations in the genes and their possible modes of action is provided in this section.

Quinolones (eg.Ciprofloxacin) affect bacterial DNA replication by interacting with proteins like DNA gyrase (GyrA) and topoisomerase IV (ParC). Mutations in these proteins in the quinolone resistance determining region (QRDR), which alter the quinolone binding site, have been shown to cause resistance¹. The β -Lactam antibiotics, penicillins and cephalosporins, inhibit bacterial cell wall synthesis by binding to transpeptidase enzymes (penicillin-binding proteins or PBPs). TEM-1 gene-containing plasmids encode a TEM-1-type β -lactamase which hydrolyzes the β -lactam ring and renders the penicillin inactive². Mutations in genes encoding penicillin-binding proteins (*penA*, *ponA1*, *penC/pilQ*), *mtrR* (repressor of MtrCDE efflux pump) and the porin, *porB1b* result in resistance to β -lactam antimicrobials¹. Mutations in *mtrR*

promoter result in overexpression of MtrCDE efflux pump, causing multi-drug resistance; while porin mutations cause a slightly lower influx of antibiotics in the cell³.

Tetracyclines inhibit protein synthesis by binding to the 30S ribosomal subunit. Plasmid-encoded *tet(M)* resembles elongation factor G (EF-G) and binds to the ribosomes causing the release of the tetracycline molecule. Mutations in ribosomal binding protein S10, encoded by *rpsJ* (V57M) results in tetracycline resistance, in strains with mutations in *penB* and *mtrR*¹. Spectinomycin inhibits translation by binding to the 30S ribosomal subunit, specifically to the 16S rRNA and 30S ribosomal protein S5p (*rpsE*). Mutations in these two genes result in resistance to spectinomycin. Macrolides inhibit protein synthesis by binding to the 50S ribosomal subunit, specifically 23S rRNA. Macrolide resistance results from mutations in 23S rRNA or by the acquisition of conjugative transposon encoded proteins which cause either modification of 23S rRNA by rRNA methylase (*erm* genes) blocking macrolide interaction or overexpression of efflux pump system (*mef* pump)⁴.

Sulfonamides inhibit the synthesis of folic acid, by targeting the dihydropteroate synthase. Mutations in this antibiotic target, *folP*, increases sulphonamide MIC⁵. Mutations in the *mtrR* DNA-binding domain affects repression resulting in overexpression of the MtrCDE efflux pump system leading to multi-drug resistance. Promoter mutations in the genes coding for efflux pumps NorM and MacAB cause resistance to fluoroquinolones and macrolides, respectively¹.

Supplementary Table 6a: List of the mutations identified through literature. The novel mutations observed in our study have been indicated in bold.

Antibiotic class	Reference	Gene	Mutation	Residue in the reference genome
Quinolone	Tanaka et al ⁶ , 2000	<i>gyrA</i>	A75	A
	Unemo and Shafer ¹ , 2012; Kivata et al ⁷ , 2019		S91F/Y	S
	Unemo and Shafer, 2012; Kivata et al, 2019		D95N/G/A	D
	Chaudhry et al ⁸ , 2002		V120L	V
Quinolone	This study	<i>parC</i>	V68A	V
	Tanaka et al, 2000		G85	G

	Unemo and Shafer, 2012; Tanaka et al, 2000		D86N	D
	Zhou et al ⁹ , 2004		S87R	S
	Unemo and Shafer, 2012		S88P	S
	Unemo and Shafer, 2012; Kivata et al, 2019		E91K/G	E
	Tanaka et al, 2000		A92	A
	Chaudhry et al ⁸ , 2002		F100Y	TTT (codon)
	Chaudhry et al, 2002		Y104 silent	TAC
	Chaudhry et al, 2002		G109 silent	GGC
	Chaudhry et al, 2002		R116H	R
	Chaudhry et al, 2002		L131 silent	CTG
Penicillin and extended spectrum cephalosporins (ESCs)	Unemo and Shafer, 2012	<i>ponA1</i> (pbp1)	L421P	L
Tetracycline	Unemo and Shafer, 2012	<i>rpsJ</i>	V57M	V
Penicillin, ESCs, tetracycline	Unemo and Shafer, 2012	<i>penC/pilQ</i>	E666K(E658 K)	E
Penicillin, cephalosporins	Unemo and Shafer, 2012	<i>penA/pbp2</i>	A311V	A
	Unemo and Shafer, 2012		I312M	I
	Unemo and Shafer, 2012		V316T/P	V
	Unemo and Shafer, 2012		D345 insertion	D
	Unemo and Shafer, 2012		T483S	T
	Unemo and Shafer, 2012		A501P/V/T	A
	Cehovin et al ¹⁰ , 2018		F504L	F
	Unemo and Shafer, 2012		N512Y	N
	Unemo and Shafer, 2012		G545S	G
	Lee et al ¹¹ , 2010		P551S/L	P
Tetracycline, penicillin, cephalosporins	Lee et al, 2010	<i>porB1B</i> (penB)	G101K/L/N	K
	Lee et al, 2010		A102D/N	G
	Unemo and Shafer, 2012		G120D/K	G
	Unemo and Shafer, 2012		A121D	A
	Kivata et al, 2019		N122	N
Sulfonamide	Fiebelkorn et al ¹² , 2005	<i>folP</i>	F31L	F
	Fiebelkorn et al, 2005		A36V	A
	Fiebelkorn et al, 2005		Q42R	Q
	Fiebelkorn et al, 2005		T66M	T
	Fiebelkorn et al, 2005		P68S/L/A/Q	P
	Fiebelkorn et al, 2005		A71 insert	-
	Fiebelkorn et al, 2005		P75S	P
	This study		E79 insertion	-

	Fiebelkorn et al, 2005		E83A	E
	Fiebelkorn et al, 2005		P84S	P
	Fiebelkorn et al, 2005		A87V/E	A
	Fiebelkorn et al, 2005		V96I	V
	Fiebelkorn et al, 2005		R102H	R
	Fiebelkorn et al, 2005		V105I	V
	Fiebelkorn et al, 2005		A111T	A
	Fiebelkorn et al, 2005		G114V	G
	Fiebelkorn et al, 2005		I115V	I
	Fiebelkorn et al, 2005		T126N	T
	Fiebelkorn et al, 2005		E128K	E
	Fiebelkorn et al, 2005		V130L	V
	Fiebelkorn et al, 2005		R135C	R
	Fiebelkorn et al, 2005		V178I	V
	Fiebelkorn et al, 2005		T188I	T
	Fiebelkorn et al, 2005		G194C/S	G
	Fiebelkorn et al, 2005		GS insertion195- 196	-
	Fiebelkorn et al, 2005		P210L	P
	Fiebelkorn et al, 2005		A215E	A
	Fiebelkorn et al, 2005		I222V	I
	Fiebelkorn et al, 2005		R228S	R
Macrolide	Unemo and Shafer, 2012	23S rRNA	A2059G	-
	Zheng et al, 2019		A2143G	
	Zheng et al, 2019		C2599T	
	Unemo and Shafer, 2012		C2611T	
Fluoroquinolone	Unemo and Shafer, 2012	<i>norM</i>	CTGACG to TTGACG	-
Macrolide	Unemo and Shafer, 2012	<i>macAB</i> -35 operon	AGAAT to TATAAT	T
Penicillin, tetracycline, macrolides, cephalosporins	Unemo and Shafer, 2012	<i>mtrR</i>	CtoT at mtr120	-
	Unemo and Shafer, 2012		del of A in 13 bp inv repeat	-
	Kivata et al, 2019	MtrR	A39	A
	Allen et al, 2013		R44H	
	Unemo and Shafer, 2012		G45D	G
	Lee et al, 2010		L47P	L
	Kivata et al, 2019		H105	H
Spectinomycin	Unemo and Shafer, 2012	16S rRNA C1192U(G 1192A)		-
Macrolide	Roberts et al ⁴ , 1999	<i>mef</i>		-
Macrolide	Roberts et al, 1999	<i>ermB/ermF</i>		-

Long-chained antibacterial fatty acids	Unemo and Shafer, 2012	FarAB (fatty acid resistance efflux transporter)		+
Spectinomycin	Unemo and Shafer, 2012	S5p/RpsE	V27Δ	V
	Ilina et al, 2013		T24P	T
	Unemo and Shafer, 2012		K28E	K
Azithromycin	Ma et al, 2020	L4p/RplD	G68C/D	G
	Ma et al, 2020		T69I	T
	Ma et al, 2020		G70D/S/A/R/ Y	G
	Ma et al, 2020		G70 duplication	-
Penicillin	Cehovin et al, 2018	beta-lactamase containing plasmids	<i>pbla</i> TEM	
Tetracycline	Cehovin et al, 2018	tet-M containing plasmids	<i>ptet</i> (M)	

Supplementary Table 6b: Sequencing depth of the regions with mutations implicated in AMR. Sequencing depth for the gene loci, *rpsJ* and *folP*, with AMR mutations listed in Table 2 of the main manuscript.

Strain id	3	12	18	57	61	100A	240	274	285	298
gene										
<i>rpsJ</i>	533	330	255	1341	67	866	73	257	118	241
<i>folP</i>	489	370	196	1247	34	843	50	215	75	168

Supplementary Table 6c: Results from AMR profiling using PathogenWatch. The AMR mutations predicted by the database PathogenWatch is given below. R Resistant, I Intermediate, - Not predicted. Out of the predicted ciprofloxacin-resistant strains, only strains 12 and 57 are resistant, 298 shows intermediate resistance whereas, strain 100A is susceptible but predicted to be resistant.

Strain ids	3	12	18	57	61	100A	240	274	285	298
Ciprofloxacin resistance	-	R	R	R	-	R	R	-	R	-
Mutation	-	gyrA_S91F/D95A	gyrA_S91F/D95A	gyrA_S91F/D95A	-	gyrA_S91F/D95A	gyrA_S91F	-	gyrA_S91F	-
Penicillin resistance	I	I	I	I	I	I	I	I	I	I
Mutation	penA_ins346D; ponA1_L421P	penA_ins346D	penA_ins346D; ponA1_L421P; porB1b_A121D	penA_ins346D; ponA1_L421P	penA_ins346D	penA_ins346D; ponA1_L421P	penA_ins346D; ponA1_L421P	penA_ins346D	penA_ins346D; ponA1_L421P	penA_ins346D
Sulfonamide resistance	R	R	R	R	R	R	R	R	R	R
Mutation	folP_R228S	folP_R228S	folP_R228S	folP_R228S	folP_R228S	folP_R228S	folP_R228S	folP_R228S	folP_R228S	folP_R228S
Tetracycline resistance	I	I	I	I	I	I	I	I	I	I
Mutation	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M	rpsJ_V57M

Supplementary Table 6d: Results from AMR profiling using CARD. The AMR mutations predicted by the database CARD is given below. Out of the predicted ciprofloxacin-resistant strains, only strains 12 and 57 are resistant, 298 shows intermediate resistance whereas, strain 100A is susceptible but predicted to be resistant.

Strain id	18	61	3	12	57	100A	240	274	285	298
Cephalosporin, Cephamycin, Penam	PBP1 1421P		PBP1 1421P		PBP1 1421P					

Cephalosporin, Cephamycin, Penam	PBP2 F504L, A510V, A516G	PBP2 F504L, A510V, A516G	PBP2 F504L, A510V, A516G	PBP2 F504L, A510V, A516G	PBP2 F504L, A510V, A516G	PBP2 F504L, A510V, A516G	PBP2 F504L, A510V, A516G, P551L		PBP2 F504L, A510V, A516G, P551L	PBP2 F504L, A510V, A516G
Fluoroquinolone	gyrA S91F			gyrA S91F	gyrA S91F	gyrA S91F	gyrA S91F		gyrA S91F	
Fluoroquinolone				parC E91G			parC E91G		parC	parC
Macrolide	mtrR A39T	mtrR A39T	mtrR A39T	mtrR A39T	mtrR A39T	mtrR A39T				
Tetracycline	rpsJ V57M	rpsJ V57M	rpsJ V57M	rpsJ V57M						
Macrolide			rpld G70D							

8. Investigation of the structural basis for antibiotic resistance mutations

Of all the mutations reported in the literature, in the genes listed above, our strains had mutations in only a few genes. Homology modelling of a few proteins was carried out to understand the basis of drug resistance, which has been discussed below.

Supplementary Table 7: Template details of homology modelling for the proteins with mutations resulting in AMR.

Protein and gene name	PDB id	Resolution	PDB details	Reference organism	% identity
DNA gyrase A (gyrA)	2XCT	3.35Å	Gyrase (GyrA-GyrB truncate) with moxifloxacin and DNA	<i>Staphylococcus aureus</i>	47.23
DNA Topoisomerase IV subunit ParC (parC)	2XKK	3.25Å	Topo IV (ParE-ParC truncate) with moxifloxacin and DNA	<i>Acinetobacter baumannii</i>	51.95

Penicillin-binding protein (<i>ponA1</i>)	3UDI	2.60Å	PBP1a in complex with penicillin G	<i>A. baumannii</i>	40.54
Porin (<i>porB1b</i>)	4GCP	1.98Å	Outer membrane protein F (OmpF) porin with Ampicillin	<i>E. coli</i>	22
Dihydropteroate synthase (<i>folP</i>)	3TZF	2.10Å	Dihydropteroate Synthase with Sulfonamide Drug Complex	<i>Yersinia pestis</i>	47.17

9. Basis of drug resistance

Ribosomal protein S10 (*rpsJ*)- V57M mutation is associated with resistance to tetracycline. From studies on the structure of the 30S ribosomal subunit from *Thermus thermophilus* (PDB id: 1HNW)¹³, this residue was seen to be close to the tetracycline-binding site in RpsJ. The presence of hydrophobic side chains at this site is thought to alter the structure and reduce the binding affinity of tetracycline¹⁴.

Ribosomal protein L4p (*rplD*)- G70 residue is predicted to make contacts with azithromycin bound to the 50S ribosome from studies in *Thermus thermophilus*¹⁵.

penA-¹⁶. The D345a residue is involved in a hydrogen bond network with catalytic serine residue, which may prevent the acylation of R1 subunit of penicillin, resulting in resistance. The mutation F504L occurs in the β 3– β 4 loop. This loop is thought to be important for the flexibility and resistance to beta-lactams, as inferred from studies in *Streptococcus pneumoniae*^{17,18}.

mtrR- The MtrR protein from *N. gonorrhoeae* has been crystallised (PDB id: 6OF0)¹⁹. The mutations A39T and H105 are observed in the α 2 helix which is a part of the DNA binding domain and α 6, respectively, which is closer to the DNA binding region, in the wild-type protein structure. A39T mutation is thought to decrease the affinity of MtrR for *mtrCDE* promoter region, leading to resistance¹⁹.

porB1b- Structure of outer membrane porin F from *E. coli* in complex with ampicillin (PDB id: 4GCP) was used as the template for homology modelling of PorB1b protein from reference strain (G120, A121, N122) and our sequenced strain 57 (D120, G121 and D122). Gly120 and Asp121 and Asn122 mutations confer intermediate resistance to penicillin and tetracycline and are located in the loop3 region which forms the pore constriction zone²⁰. The mutated residues are shown in Figures S1a-c. These side chains could be lining a substrate translocation pathway, consistent with observations that mutations decrease antibiotic permeability¹.

ponA1 has only one reported mutation in *N. gonorrhoeae*, L421P, which occurs about 40 residues to the upstream of catalytic residue S460 and confers resistance to penicillin and extended-spectrum cephalosporins¹⁸. We modelled the structure of wild-type and mutant *ponA1* from strain 3 using the template, *Acinetobacter baumannii* PBP1a in complex with penicillin G (PDB id: 3UDI)²¹. The homology model revealed that the mutation occurs in the C-terminal end of the ODD (outer-membrane PBP1A docking domain), which acts as a linker between the transpeptidase domain and glycosyltransferase domain (Figures S2a-c)²¹. The domain has been suggested to serve as a structural intermediary between the two domains¹⁷ and in the formation of a hydrophobic patch to selectively regulate substrate entry into the catalytic pocket²², based on studies in other bacteria.

10. Phylogenetic analysis with strains across the world

Supplementary Table 8: Details for strains used in phylogeny analysis. The analysis was carried out using the genome comparator module of BIGSdb, and details like country and antibiotic resistance were derived from PubMLST using a keyword search for strain ids. Colour code: Dark yellow with red text- Resistant, Cream with green text- Intermediate.

id	isolate	country	continent	penicillin	ceftriaxone	ciprofloxacin	tetracycline	cefixime	azithromycin	Doxycycline	spectinomycin
26532	ITOH27	Japan	Asia								
26533	FC007	Japan	Asia								
26534	FC061	Japan	Asia								
26535	HI019	Japan	Asia								
27394	GCGS0235	USA	North America	2	0.06	16	4	0.25	0.25		

27395	GCGS0076	USA	North America	1	0.008	8	2	0.015	0.25		
27396	GCGS0149	USA	North America	1	0.03	0.015	1	0.25	0.5		
27397	GCGS0229	USA	North America	2	0.06	16	2	0.25	0.5		
27398	GCGS0139	USA	North America	4	0.125	32	4	0.25	1		
27399	GCGS0185	USA	North America	2	0.06	16	2	0.25	0.25		
27400	GCGS0081	USA	North America	2	0.06	16	1	0.25	0.125		
27401	GCGS0077	USA	North America	4	0.06	16	2	0.25	1		
27402	GCGS0201	USA	North America	1	0.063	0.004	1	0.25	0.5		
27403	GCGS0213	USA	North America	1	0.063	0.004	0.5	0.5	0.5		
27712	98-119	Japan	Asia	32		<0.008					
27713	98-127	Japan	Asia			<0.008					
27714	11-43	Japan	Asia			<0.008					
27715	11-44	Japan	Asia			0.031					
27716	11-60	Japan	Asia			0.5					
27717	11-59	Japan	Asia			0.063					
31461	WHO_O	Canada	North America	32	0.032	0.008					
31505	318/-10	France	Europe	1	2	32	2	3	0.38		
31562	WHO_F	Canada	North America	0.032	0.002	0.004					
31566	WHO_P	USA	North America	0.25	0.004	0.004					
31586	989000380	Russia	Asia	0.75	0.004	0.002					
31587	989000257	Russia	Asia	0.125	0.002	0.003					
31588	989000326	Russia	Asia	0.016	0.002	0.002					
31596	05_590_24 6	Russia	Asia	0.75	0.016	6	1	0.016	0.125		
31597	05_590_26 9	Russia	Asia	0.38	0.008	8	1	0.016	0.125		
31598	05_590_29 0	Russia	Asia	0.125	0.003	0.006	1	0.016	0.38		
31663	WHO M	Australia	Oceania	8	0.012	2	1	0.016	0.25		
31664	WHO L	Australia	Oceania	2	0.125	32	4	0.25	0.5		
31665	WHO J	Australia	Oceania	32	0.023	24	3	0.016	0.38		
31666	WHO I	Australia	Oceania	3	0.032	0.75	3	0.032	0.25		
31695	WHO_K	Japan	Asia	2	0.064	32	2	0.5	0.25		
31758	WHO_G	Australia	Oceania	0.5	0.008	0.125	32	0.016	0.25		
31761	05_590_34 2	Russia	Asia	0.064	0.032	0.75	1	0.023	1		

31764	WHO_N	Australia	Oceania	8	0.004	4	16	0.016	0.125		
31768	05_590_26 4	Russia	Asia	0.064	0.094	0.75	1	0.023	1		
31799	05_590_33 9	Russia	Asia	0.12	0.002	0.003	1	0.016	0.094		
31805	05_590_24 9	Russia	Asia	2	0.032	0.016	3	0.023	0.5		
31931	WHO M	Unknown									
31932	WHO L	Unknown									
31933	WHO J	Unknown									
31934	WHO I	Unknown									
34748	SK708	Canada	North America								
34749	SK6987	Canada	North America								
34750	SK7461	Canada	North America								
34751	SK7842	Canada	North America								
34752	SK13777	Canada	North America								
34753	SK14515	Canada	North America								
34754	SK15454	Canada	North America								
34755	SK16259	Canada	North America								
34756	SK16942	Canada	North America								
34757	SK17973	Canada	North America								
36238	51212	Kenya	Africa								
36240	52262	Kenya	Africa								
36243	57547	Kenya	Africa								
36244	56873	Kenya	Africa								
36245	44568	Kenya	Africa								
36246	61467	Kenya	Africa								
36247	62017	Kenya	Africa								
36248	43305	Kenya	Africa								
36249	51451	Kenya	Africa								
36250	58767	Kenya	Africa								
36251	63179	Kenya	Africa				0.25		0.032	0.19	
36253	61450	Kenya	Africa								
36255	45453	Kenya	Africa				12		0.032	4	
36256	45676	Kenya	Africa								
36257	51960	Kenya	Africa								
36259	61580	Kenya	Africa								
36261	48871	Kenya	Africa								
36263	48501	Kenya	Africa								
36266	60096	Kenya	Africa								

36267	55496	Kenya	Africa								
36268	T060	Kenya	Africa								
36269	52263	Kenya	Africa								
36270	59688	Kenya	Africa								
36271	50659	Kenya	Africa	64			12		0.094	4	
36273	55798	Kenya	Africa								
36274	63518	Kenya	Africa								
36275	51468	Kenya	Africa	0.19			12		0.19	2	
36276	51645	Kenya	Africa								
36277	59012	Kenya	Africa								
36279	60243	Kenya	Africa								
36280	47956	Kenya	Africa								
36281	47686	Kenya	Africa								
36282	45029	Kenya	Africa	4			0.5		0.047	0.38	
36283	47147	Kenya	Africa								
36284	44593	Kenya	Africa								
36285	43346	Kenya	Africa								
36287	43781	Kenya	Africa								
36289	42974	Kenya	Africa	12			16		0.125	6	
36290	47983	Kenya	Africa								
36291	60755	Kenya	Africa								
36292	60709	Kenya	Africa								
36293	43000	Kenya	Africa								
36294	43038	Kenya	Africa								
36295	46146	Kenya	Africa								
36296	44569	Kenya	Africa	8			8		0.064	2	
36297	52492	Kenya	Africa								
36298	T101	Kenya	Africa								
36299	46445	Kenya	Africa								
39081	64204	Kenya	Africa				16		0.125	12	
39082	64500	Kenya	Africa	0.38			16		0.125	8	
39083	64579	Kenya	Africa								
39084	64605	Kenya	Africa								
39085	64680	Kenya	Africa								
39086	64586	Kenya	Africa								
39087	64361	Kenya	Africa								
39088	64755	Kenya	Africa								
39089	64203	Kenya	Africa								
39090	65080	Kenya	Africa								
39091	65318	Kenya	Africa								
39092	65320	Kenya	Africa								
39093	65551	Kenya	Africa								
39094	65600	Kenya	Africa	0.094			0.25		0.016	0.25	
39095	65737	Kenya	Africa								
39096	56474	Kenya	Africa								

39097	56327	Kenya	Africa							
39098	56682	Kenya	Africa	0.094		3			4	
39099	56835	Kenya	Africa							
39100	57568	Kenya	Africa							
39101	63971	Kenya	Africa							
39103	45858	Kenya	Africa							
39104	45722	Kenya	Africa							
39105	44941	Kenya	Africa			4		0.047	4	
39106	45388	Kenya	Africa							
39107	45715	Kenya	Africa							
39108	45910	Kenya	Africa							
39109	43208 -1	Kenya	Africa							
39112	44271	Kenya	Africa							
39113	42876	Kenya	Africa	192		12			1.5	
39114	44254	Kenya	Africa							
39115	43306	Kenya	Africa							
39116	46745	Kenya	Africa							
39117	47244	Kenya	Africa							
39118	47954	Kenya	Africa							
39119	47547	Kenya	Africa	16		16			2	
39120	47548	Kenya	Africa							
39121	48183	Kenya	Africa							
39122	48763	Kenya	Africa							
39123	48437	Kenya	Africa							
39124	48563	Kenya	Africa							
39125	48848	Kenya	Africa							
39126	48213	Kenya	Africa							
39127	48502	Kenya	Africa							
39128	48406	Kenya	Africa							
39129	50040	Kenya	Africa							
39130	49506	Kenya	Africa							
39131	49676	Kenya	Africa							
39132	49719	Kenya	Africa							
39133	50869	Kenya	Africa							
39134	51751	Kenya	Africa							
39135	52057	Kenya	Africa							
39137	65907	Kenya	Africa							
39138	66098	Kenya	Africa	0.19		12		0.125	8	
39139	42978	Kenya	Africa							
39512	8173	Sweden	Europe							
39513	23592	Sweden	Europe							
39514	14037	Sweden	Europe							
39515	12521	Sweden	Europe							
39516	1423	Sweden	Europe							
39517	84733	Sweden	Europe							
39518	23664	Sweden	Europe							


39519	23454	Sweden	Europe								
39520	80094	Sweden	Europe								
39521	24185	Sweden	Europe								
40839	Ng626	Italy	Europe	1		32					
41316	Ng630	Italy	Europe	0.25		32					
41345	Ng632	Italy	Europe	0.23		0.008					
41346	Ng741	Italy	Europe	0.5		8					
41347	Ng755	Italy	Europe	0.25	0.016	32					
41348	Ng807	Italy	Europe	32		0.006					
41349	Ng812	Italy	Europe	32		0.002					
41350	Ng849	Italy	Europe	0.5	0.012	32					
41351	Ng859	Italy	Europe	32		8					
41352	Ng885	Italy	Europe	0.125	0.006	3					
42071	ESP_001	Spain	Europe								
42072	ESP_002	Spain	Europe								
42073	ESP_003	Spain	Europe								
42074	ESP_004	Spain	Europe								
42075	ESP_005	Spain	Europe								
42076	ESP_006	Spain	Europe								
42077	ESP_007	Spain	Europe								
42078	ESP_008	Spain	Europe								
42079	ESP_009	Spain	Europe								
42080	ESP_010	Spain	Europe								
45012	EXNG204	Australia	Oceania	0.25	0.008	<=0.03					
45015	EXNG206	Australia	Oceania	0.25	0.008	<=0.03					
45016	EXNG209	Australia	Oceania	0.125	0.008	<=0.03					
45017	EXNG210	Australia	Oceania	0.06	0.008	<=0.03					
45018	EXNG213	Australia	Oceania	0.125	0.016	<=0.03					
45019	EXNG219	Australia	Oceania	0.125	0.008	<=0.03					
45020	EXNG214	Australia	Oceania	0.125	0.008	<=0.03					
45021	EXNG225	Australia	Oceania	0.125	0.008	<=0.03					
45022	EXNG226	Australia	Oceania	>2	0.008	1-2					
47026	GNCWGS_03GN_87	China	Asia								
47027	GNCWGS_03SQ_89	China	Asia								
47028	GNCWGS_04AV_95	China	Asia								
47029	GNCWGS_04CD	China	Asia								
47030	GNCWGS_05OP	China	Asia								

47031	GNCWGS_061Z	China	Asia								
47032	GNCWGS_0712_63	China	Asia								
47033	GNCWGS_0747_64	China	Asia								
47034	GNCWGS_075N_65	China	Asia								
47035	GNCWGS_07AD_68	China	Asia								
47347	SRR334347_2	UK [England]	Europe								
47348	SRR334347_3	UK [England]	Europe								
47349	SRR334347_4	UK [England]	Europe								
47350	SRR334347_5	UK [England]	Europe								
47351	SRR334347_6	UK [England]	Europe								
47352	SRR334347_7	UK [England]	Europe								
47354	SRR334348_0	UK [England]	Europe								
47355	SRR334348_1	UK [England]	Europe								
47356	SRR334348_2	UK [England]	Europe								
47357	SRR334348_3	UK [England]	Europe								
54271	LRRBGS_0039	Brazil	South America	4	0.032	16	4	0.125	2		
54272	LRRBGS_0040	Brazil	South America	8	0.032	16	4	0.125	2		
54273	LRRBGS_0041	Brazil	South America	2	0.015	4	1	0.125	2		
54274	LRRBGS_0042	Brazil	South America	16	0.015	4	32	0.125	0.5		
54275	LRRBGS_0043	Brazil	South America	4	0.032	16	4	0.125	2		
54276	LRRBGS_0044	Brazil	South America	4	0.032	16	4	0.125	2		
54277	LRRBGS_0045	Brazil	South America	8	0.032	16	4	0.125	8		
54278	LRRBGS_0046	Brazil	South America	16	0.015	1	32	0.125	1		
54279	LRRBGS_0047	Brazil	South America	4	0.032	16	4	0.125	2		
54280	LRRBGS_0048	Brazil	South America	8	0.064	16	4	0.125	4		
59511	KNY_NGA_MR/9	Kenya	Africa								
60436	KNY_NGA_MR/1	Kenya	Africa								


60437	KNY_NGA MR9p	Kenya	Africa								
60501	KNY_NGA MR2	Kenya	Africa								
60502	KNY_NGA MR3	Kenya	Africa								
60503	KNY_NGA MR4	Kenya	Africa								
60504	KNY_NGA MR5	Kenya	Africa								
60505	KNY_NGA MR6	Kenya	Africa								
60506	KNY_NGA MR7	Kenya	Africa								
60507	KNY_NGA MR8	Kenya	Africa								
60508	KNY_NGA MR10	Kenya	Africa								
60509	KNY_NGA MR11	Kenya	Africa								
60510	KNY_NGA MR23	Kenya	Africa								
60511	KNY_NGA MR14	Kenya	Africa								
60512	KNY_NGA MR20	Kenya	Africa								
60513	KNY_NGA MR17	Kenya	Africa								
60514	KNY_NGA MR18	Kenya	Africa								
60515	KNY_NGA MR19	Kenya	Africa								
60516	KNY_NGA MR15	Kenya	Africa								
60517	KNY_NGA MR21	Kenya	Africa								
60518	KNY_NGA MR22	Kenya	Africa								
60519	KNY_NGA MR13	Kenya	Africa								
61332	WHO_V	Sweden	Europe	>32	0.047	>32	3	0.016	>256		
61379	WHO_Z	Australia	Oceania	2	0.5	>32	3	1.5	1		
62968	WHOF	Unknown									
88855	WHO G	Thailand	Asia								
88856	WHO K	Japan	Asia								
88857	WHO L	Unknown									
88858	WHO M	Philippines	Asia								
88859	WHO N	Australia	Oceania								
88860	WHO O	Canada	North America								

88861	WHO P	USA	North America								
89182	15MUS-PI003	South Africa	Africa								
89183	15MUS-PI044	South Africa	Africa								
89185	15MUS-PI098	South Africa	Africa								
89186	17MUS-AH083	South Africa	Africa								
89187	17MUS-AH094	South Africa	Africa								
89188	17MUS-AH118	South Africa	Africa								
89189	17MUS-AH035	South Africa	Africa								
89190	15MUS-PI063	South Africa	Africa								
89194	17MUS-AH070	South Africa	Africa								
89195	15MUS-PI091	South Africa	Africa								
89513	G03-2019	Chile	South America	2	0.004	0.002	0.25	< 0.016	0.5		16
89514	G137-2019	Chile	South America	64	0.004	1	0.25	< 0.016	0.064		8
89515	G156-2019	Chile	South America	2	0.008	4	0.5	< 0.016	0.25		16
89516	G182-2019	Chile	South America	32	0.008	0.5	64	< 0.016	1		16
89517	G207-2019	Chile	South America	0.125	0.004	0.002	0.25	< 0.016	0.25		8
89518	G225-2019	Chile	South America	64	0.004	2	0.25	< 0.016	0.125		8
89519	G235-2019	Chile	South America	2	0.004	4	0.25	< 0.016	0.25		16
89520	G242-2019	Chile	South America	32	0.016	2	16	0.064	0.25		16
93850	G11-2019	Chile	South America	16	0.004	0.5	0.25	< 0.016	0.032		8
93851	G17-2019	Chile	South America	0.25	0.004	2	0.5	< 0.016	> 256		16

Figures



Supplementary Figure 3: The modelled structure of the *porB1b* complex with ampicillin (a). A close-up of the antibiotic-binding pocket showing ampicillin (red) and the residues G120, A121, N122 in reference strain structure (b) and in the triple mutant D120, G121 and D122 (magenta) (c). The polar contacts for the antibiotic are shown as yellow dashes.



Supplementary Figure 4: The modelled structure of the *ponA1* complex with penicillin (a). A close-up of the antibiotic-binding pocket showing penicillin G (red), L421 (magenta) in wild-

type structure (b) and L421P mutant (magenta) (c). The polar contacts for the antibiotic are shown as yellow dashes.

References

1. Unemo, M. & Shafer, W. M. Antibiotic resistance in *Neisseria gonorrhoeae*: origin, evolution, and lessons learned for the future. *Ann. N. Y. Acad. Sci.* **1230**, E19-28 (2011).
2. Nakayama, S.-I. *et al.* Molecular analyses of TEM genes and their corresponding penicillinase-producing *Neisseria gonorrhoeae* isolates in Bangkok, Thailand. *Antimicrob. Agents Chemother.* **56**, 916–920 (2012).
3. Suay-García, B. & Pérez-Gracia, M. T. Drug-resistant *Neisseria gonorrhoeae*: latest developments. *Eur. J. Clin. Microbiol. Infect. Dis.* **36**, 1065—1071 (2017).
4. Roberts, M. C. *et al.* Erythromycin-resistant *Neisseria gonorrhoeae* and oral commensal *Neisseria* spp. carry known rRNA methylase genes. *Antimicrob. Agents Chemother.* **43**, 1367–1372 (1999).
5. Griffith, E. C. *et al.* The Structural and Functional Basis for Recurring Sulfa Drug Resistance Mutations in *Staphylococcus aureus* Dihydropteroate Synthase. *Front. Microbiol.* **9**, 1369 (2018).
6. Tanaka, M., Nakayama, H., Haraoka, M. & Saika, T. Antimicrobial resistance of *Neisseria gonorrhoeae* and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998. *J. Clin. Microbiol.* **38**, 521–525 (2000).
7. Kivata, M. W. *et al.* *gyrA* and *parC* mutations in fluoroquinolone-resistant *Neisseria gonorrhoeae* isolates from Kenya. *BMC Microbiol.* **19**, 76 (2019).
8. Chaudhry, U., Ray, K., Bala, M. & Saluja, D. Mutation patterns in *gyrA* and *parC* genes of ciprofloxacin resistant isolates of *Neisseria gonorrhoeae* from India. *Sex. Transm. Infect.* **78**, 440–444 (2002).
9. Zhou, W. *et al.* Detection of *gyrA* and *parC* mutations associated with ciprofloxacin resistance in *Neisseria gonorrhoeae* by use of oligonucleotide biochip technology. *J. Clin. Microbiol.* **42**, 5819–5824 (2004).

10. Cehovin, A. *et al.* Identification of Novel *Neisseria gonorrhoeae* Lineages Harboring Resistance Plasmids in Coastal Kenya. *J. Infect. Dis.* **218**, 801–808 (2018).
11. Lee, S.-G. *et al.* Various *penA* mutations together with *mtrR*, *porB* and *ponA* mutations in *Neisseria gonorrhoeae* isolates with reduced susceptibility to cefixime or ceftriaxone. *J. Antimicrob. Chemother.* **65**, 669–675 (2010).
12. Fiebelkorn, K. R., Crawford, S. A. & Jorgensen, J. H. Mutations in *folP* associated with elevated sulfonamide MICs for *Neisseria meningitidis* clinical isolates from five continents. *Antimicrob. Agents Chemother.* **49**, 536–540 (2005).
13. Carter, A. P. *et al.* Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. *Nature* **407**, 340–348 (2000).
14. Hu, M., Nandi, S., Davies, C. & Nicholas, R. A. High-level chromosomally mediated tetracycline resistance in *Neisseria gonorrhoeae* results from a point mutation in the *rpsJ* gene encoding ribosomal protein S10 in combination with the *mtrR* and *penB* resistance determinants. *Antimicrob. Agents Chemother.* **49**, 4327–4334 (2005).
15. Ma, K. C. *et al.* Increased power from bacterial genome-wide association conditional on known effects identifies *Neisseria gonorrhoeae* macrolide resistance mutations in the 50S ribosomal protein L4. *bioRxiv* (2020). doi:10.1101/2020.03.24.006650
16. Singh, A. *et al.* Mutations in penicillin-binding protein 2 from cephalosporin-resistant *Neisseria gonorrhoeae* hinder ceftriaxone acylation by restricting protein dynamics. *J. Biol. Chem.* **295**, 7529–7543 (2020).
17. Job, V., Carapito, R., Vernet, T., Dessen, A. & Zapun, A. Common alterations in PBP1a from resistant *Streptococcus pneumoniae* decrease its reactivity toward beta-lactams: structural insights. *J. Biol. Chem.* **283**, 4886–4894 (2008).
18. Zapun, A., Morlot, C. & Taha, M.-K. Resistance to β -Lactams in *Neisseria ssp* Due to Chromosomally Encoded Penicillin-Binding Proteins. *Antibiot. (Basel, Switzerland)* **5**, (2016).
19. Beggs, G. A. *et al.* Structural, Biochemical, and In Vivo Characterization of *MtrR*-Mediated Resistance to Innate Antimicrobials by the Human Pathogen *Neisseria gonorrhoeae*. *J. Bacteriol.* **201**, (2019).
20. Olesky, M., Zhao, S., Rosenberg, R. L. & Nicholas, R. A. Porin-Mediated Antibiotic

Resistance in *Neisseria gonorrhoeae*: Ion, Solute, and Antibiotic Permeation through PIB Proteins with penB Mutations. *J. Bacteriol.* **188**, 2300 LP – 2308 (2006).

21. Han, S. *et al.* Distinctive attributes of β -lactam target proteins in *Acinetobacter baumannii* relevant to development of new antibiotics. *J. Am. Chem. Soc.* **133**, 20536–20545 (2011).
22. Contreras-Martel, C. *et al.* Crystal structure of penicillin-binding protein 1a (PBP1a) reveals a mutational hotspot implicated in beta-lactam resistance in *Streptococcus pneumoniae*. *J. Mol. Biol.* **355**, 684–696 (2006).